CABACabaletta Bio, Inc.
$1.94-16% 1Y
$1.94
$1.8852 weeks$4.15
CABA as reported
- Net income
- −$181M
Net income · +26% year on year · trailing twelve months to Q2 2026
- Free cash flow
- −$154M
Free cash flow · +45% year on year · trailing twelve months to Q2 2026
- EPS
- −$1.52
EPS · −44% year on year · trailing twelve months to Q2 2026
Details›
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Net income | −$181M | +26% | Q2 2026 |
| EPS | −$1.52 | −44% | Q2 2026 |
| ROE | −130% | n/a | Q2 2026 |
| ROA | −94% | n/a | Q2 2026 |
| Free cash flow | −$154M | +45% | Q2 2026 |
Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.
Cabaletta Bio, Inc. (CABA) · Net incomeNet incomeCabaletta Bio, Inc. (CABA)